Dômes Pharma: The latest figures, news and market research on Dômes Pharma

Turnover: 90 million EUR (2023)

Country: France

Veterinary laboratory
An independent, family-owned group, Dômes Pharma has been an ETI since 1947, with over 380 employees at 6 sites in France, England and Germany, and consolidated sales of €79 million (2020).
For over 70 years, the Group has been developing, manufacturing and marketing solutions for the health and well-being of pets.
4 subsidiaries

Dôme Pharma makes its first acquisition in the United States 14/09/2023

The family-run laboratory based in Pont-du-Château, in the Puy-de-Dôme region of France, employs 400 people at seven sites, and will achieve consolidated sales of €87 million by 2022.
Specialist in the health and well-being of pets
Acquisition of SentrX Animal Care, an American company specializing in veterinary ophthalmology, its core business.
Around 15 employees, $8 million in sales by 2022
Dômes Pharma is aiming to generate at least 35% of its revenues outside France by 2025, compared with 15% today.
The United States and Canada should drive this growth
The family-owned laboratory is already present in the UK, Germany and Spain, where it has opened subsidiaries.
With Biocanina and TVM in veterinary health (85% of its business), Dômes Pharma claims a leading position in ophthalmology and in the management of intoxications and epilepsy in companion animals.
It also owns Léro and Aspivenin in human health

Other companies mentioned: